Chromocell Therapeutics Net Income
| CHRODelisted Stock | USD 16.50 1.25 8.20% |
As of the 1st of March, Chromocell Therapeutics shows the Mean Deviation of 5.31, downside deviation of 6.14, and Risk Adjusted Performance of 0.0437. Chromocell Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Chromocell Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Chromocell Therapeutics' valuation are provided below:Chromocell Therapeutics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Chromocell |
Search Suggestions
| CH | Aberdeen Chile | ETFDelisted |
| CHSCL | CHS Inc CL | Company |
| CHA | Chagee Holdings Limited | Company |
| CHI | Calamos Convertible Opportunities | Fund |
| CHB | CHB | ETF |
| CHP | CHP | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Chromocell Therapeutics reported net income of (7.96 Million). This is 102.33% lower than that of the Biotechnology sector and 111.36% lower than that of the Health Care industry. The net income for all United States stocks is 101.39% higher than that of the company.
Chromocell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chromocell Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chromocell Therapeutics could also be used in its relative valuation, which is a method of valuing Chromocell Therapeutics by comparing valuation metrics of similar companies.Chromocell Therapeutics is currently under evaluation in net income category among its peers.
Chromocell Fundamentals
| Return On Asset | -1.89 | |||
| Current Valuation | 91.42 M | |||
| Shares Outstanding | 6.6 M | |||
| Shares Owned By Insiders | 53.88 % | |||
| Shares Owned By Institutions | 13.60 % | |||
| Number Of Shares Shorted | 76.91 K | |||
| Price To Book | 4.11 X | |||
| Gross Profit | 272.31 K | |||
| EBITDA | (7.57 M) | |||
| Net Income | (7.96 M) | |||
| Total Debt | 2.19 M | |||
| Book Value Per Share | (6.79) X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Short Ratio | 0.88 X | |||
| Earnings Per Share | (12.00) X | |||
| Target Price | 8.5 | |||
| Market Capitalization | 8.9 M | |||
| Total Asset | 1.37 M | |||
| Retained Earnings | (21.47 M) | |||
| Working Capital | (2.71 M) | |||
| Current Asset | 317 K | |||
| Current Liabilities | 166 K | |||
| Net Asset | 1.37 M |
About Chromocell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chromocell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chromocell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chromocell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Chromocell Stock
If you are still planning to invest in Chromocell Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chromocell Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Transaction History View history of all your transactions and understand their impact on performance |